Verastem, Inc.
VSTMVerastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
Drugs in Pipeline
10
Phase 3 Programs
1
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
avutometinib and sotorasib Phase 2 Est. Readout
Primary completion for avutometinib and sotorasib trial (NCT05074810) in Non Small Cell Lung Cancer
Source2 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
avutometinib
Low Grade Serous Ovarian Cancer
avutometinib (VS-6766)
Low Grade Ovarian Serous Adenocarcinoma
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
KRAS Activating Mutation
Avutometinib (VS-6766) + Defactinib (VS-6063)
Low Grade Serous Ovarian Cancer
defactinib (VS-6063)
Non Small Cell Lung Cancer
avutometinib (VS-6766) and adagrasib
Non Small Cell Lung Cancer
avutometinib and sotorasib
Non Small Cell Lung Cancer
avutometinib (VS-6766) and Defactinib
Non Small Cell Lung Cancer
VS-7375
Pancreatic Ductal Adenocarcinoma
cetuximab
Pancreatic Ductal Adenocarcinoma (PDAC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
avutometinib | Phase 3 | Low Grade Serous Ovarian Cancer | - | - |
avutometinib (VS-6766) | Phase 2 | Low Grade Ovarian Serous Adenocarcinoma | - | - |
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | Phase 2 | KRAS Activating Mutation | - | - |
Avutometinib (VS-6766) + Defactinib (VS-6063) | Phase 2 | Low Grade Serous Ovarian Cancer | - | - |
defactinib (VS-6063) | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and adagrasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib and sotorasib | Phase 2 | Non Small Cell Lung Cancer | - | - |
avutometinib (VS-6766) and Defactinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
VS-7375 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
cetuximab | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | - | - |